FDA Awards Orphan Drug Designation to Losmapimod for Treatment of FSHD
January 30th 2020Although there are no approved therapies for FSHD, researchers at Fulcrum Therapeutics discovered that inhibition of p38α/β reduced expression of the DUX4 gene in muscle cells derived from patients with FSHD.
Read More
Intravenous Iron Receives FDA Approval for Adults with Iron Deficiency Anemia
January 30th 2020Iron deficiency anemia is a condition that affects nearly 1 billion people globally,1 in which the blood lacks adequate healthy red blood cells, often leaving those with the condition tired and short of breath.2
Read More
FDA Grants Priority Review to Dupilumab for Atopic Dermatitis in Children
January 28th 2020Dupilumab has been granted priority review as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.
Read More
New Drug Combination Maintains Quality of Life for Patients with Colorectal, Liver Cancers
January 27th 2020Two large studies demonstrating patient-reported outcomes showed that quality of life was maintained longer with newer drug combinations compared with standard of care for the treatment of patients with a specific type of colorectal cancer (CRC) and unresectable hepatocellular carcinoma (HCC). The results were presented at the 2020 Gastrointestinal Cancers Symposium in San Francisco, California, from January 23-25.
Read More